Featured Research

from universities, journals, and other organizations

Levodopa better than newer drugs for long-term treatment of Parkinson's, largest-ever trial shows

Date:
June 10, 2014
Source:
The Lancet
Summary:
For long-term treatment of newly diagnosed Parkinson's disease (PD), the old drug levodopa provides better mobility and a higher quality of life than the two main alternatives, dopamine agonists and monoamine oxidase type B inhibitors, according to the largest-ever trial of PD treatment.

For long-term treatment of newly diagnosed Parkinson's disease (PD), the old drug levodopa provides better mobility and a higher quality of life than the two main alternatives, dopamine agonists (DA) and monoamine oxidase type B inhibitors (MAOBI), according to the largest-ever trial of PD treatment (PD MED), published in The Lancet.

Related Articles


PD is the second most common neurodegenerative disorder (after Alzheimer's) in the UK, with 8000 new cases each year and over 100 000 people living with the disease. The most widely used treatment is the drug levodopa, although after prolonged use patients can develop involuntary muscle spasms (dyskinesias) and motor fluctuations (movement problems). There is less risk of developing these complications with DAs or with MAOBIs than with levodopa, but other side effects including nausea, hallucinations, oedema, and sleep disturbance are increased with these newer drugs.

"Previous studies included too few patients, had short follow-up, and focused on the clinicians' assessments of motor symptoms rather than asking patients how the drugs affected their overall quality of life. So, for many years there has been uncertainty about the risks and benefits of starting treatment with these different classes of PD drugs"*, explains study leader Professor Richard Gray from the University of Oxford in the UK.

The PD MED trial randomly assigned 1620 people with early PD to levodopa-sparing therapy (DA or MAOBI) or levodopa. With up to 7 years of follow-up, self-reported scores on scales measuring mobility and quality of life showed small but persistent benefits of starting treatment with levodopa rather than the other drugs. Patients in the levodopa group also reported significantly better scores on the activities of daily living, stigma, cognition, communication, and bodily discomfort scales than those taking levodopa-sparing therapy despite more involuntary muscle spasms.

According to Professor Gray, "Although the differences in favour of levodopa are small, when you consider the short- and long-term benefits, side-effects, quality of life for patients, and costs, the old drug levodopa is still the best initial treatment strategy for most patients."

He adds, "In current clinical practice, most patients younger than 70 years are treated initially with a DA to avoid levodopa-related motor complications. However, we found levodopa better than the more expensive DAs at all ages."

Professor Carl Clarke, the clinical coordinator of the study from the University of Birmingham, UK, added, "The PD MED trial is the largest drug trial ever performed in Parkinson's disease. It is likely to change clinical practice worldwide, with the majority of patients from now on starting therapy with levodopa."

Writing in a linked Comment, Professor Anthony Lang and Dr Connie Marras from Toronto Western Hospital, Ontario, Canada say, "PD MED provides reassuring data showing that in most patients with Parkinson's disease, who have an older age of onset, how treatment is initiated generally does not matter because outcomes are very similar…Finally, and perhaps most importantly, the results of this study will help to persuade physicians and reassure patients that the fears that have served as the groundwork in establishing levodopa phobia -- that often results in patients experiencing unnecessary and easily managed disability and reduction in quality of life in the early years of their disease -- are unfounded."


Story Source:

The above story is based on materials provided by The Lancet. Note: Materials may be edited for content and length.


Journal Reference:

  1. PD MED Collaborative Group. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. The Lancet, 2014; DOI: 10.1016/S0140-6736(14)60683-8

Cite This Page:

The Lancet. "Levodopa better than newer drugs for long-term treatment of Parkinson's, largest-ever trial shows." ScienceDaily. ScienceDaily, 10 June 2014. <www.sciencedaily.com/releases/2014/06/140610205305.htm>.
The Lancet. (2014, June 10). Levodopa better than newer drugs for long-term treatment of Parkinson's, largest-ever trial shows. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2014/06/140610205305.htm
The Lancet. "Levodopa better than newer drugs for long-term treatment of Parkinson's, largest-ever trial shows." ScienceDaily. www.sciencedaily.com/releases/2014/06/140610205305.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Nurse Nina Pham Cured of Ebola

Texas Nurse Nina Pham Cured of Ebola

AFP (Oct. 25, 2014) — An American nurse who contracted Ebola while caring for a Liberian patient in Texas has been declared free of the virus and will leave the hospital. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins